Director at Puma Biotech (PBYI) sells 27K shares after RSU grant

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

PUMA Biotechnology director Adrian Senderowicz reported both an equity grant and a stock sale. On June 11, 2026, he received 27,000 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service.

On June 12, 2026, he sold 27,000 shares of Common Stock in an open-market transaction at a weighted average price of $7.1967 per share, with individual sale prices ranging from $6.98 to $7.32. The sale was effected pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025, and he held 27,000 shares directly after the transactions.

Insider Trade Summary 10b5-1

Net Seller: 27,000 shares ($194,311)

Net Sell 2 txns

Insider Senderowicz Adrian

Role null

Sold 27,000 shs ($194K)

Type	Security	Shares	Price	Value
Sale	Common Stock	27,000	$7.1967	$194K
Grant/Award	Common Stock	27,000	$0.00	--

Holdings After Transaction: Common Stock — 27,000 shares (Direct, null)

Footnotes (1)

Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 27,000 shares Weighted average sale price: $7.1967 per share RSUs granted: 27,000 units +2 more

5 metrics

Shares sold 27,000 shares Common Stock sold on June 12, 2026

Weighted average sale price $7.1967 per share Open-market sale on June 12, 2026

RSUs granted 27,000 units Restricted Stock Units granted on June 11, 2026

Post-transaction holdings 27,000 shares Shares of Common Stock held directly after June 12, 2026 sale

Sale price range $6.98–$7.32 per share Multiple trades within this range on June 12, 2026

Key Terms

Restricted Stock Units, 10b5-1(c) plan, weighted average price

3 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 03-12-2025"

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 08:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Senderowicz Adrian

(Last)

(First)

(Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BOULEVARD, SUITE 1700

(Street)

LOS ANGELES

CALIFORNIA

90024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		A		27,000	A	$0⁽¹⁾	54,000	D
Common Stock	06/12/2026		S⁽²⁾		27,000	D	$7.1967⁽³⁾	27,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

2. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Gordon Esplin as attorney-in-fact for Adrian Senderowicz	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Adrian Senderowicz report at PUMA Biotechnology (PBYI)?

Adrian Senderowicz reported receiving 27,000 Restricted Stock Units and selling 27,000 shares of Common Stock. The grant occurred on June 11, 2026, and the open-market sale followed on June 12, 2026, under a pre-adopted Rule 10b5-1(c) trading plan.

How many PUMA Biotechnology (PBYI) shares did the director sell and at what price?

He sold 27,000 shares of PUMA Biotechnology Common Stock at a weighted average price of $7.1967 per share. The individual sale prices ranged from $6.98 to $7.32, reflecting multiple trades executed within that price band on June 12, 2026.

What equity award did the PUMA Biotechnology (PBYI) director receive in this Form 4?

He received 27,000 Restricted Stock Units of PUMA Biotechnology Common Stock. These RSUs vest in full on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual shareholder meeting, contingent on his continued service with the company.

When do the Restricted Stock Units for the PUMA Biotechnology (PBYI) director vest?

The 27,000 Restricted Stock Units vest in full on the earlier of the one-year anniversary of the June 11, 2026 grant or the annual shareholder meeting following that date. Vesting remains subject to the director’s continued service with PUMA Biotechnology.

Was the PUMA Biotechnology (PBYI) director’s stock sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes that the transactions occurred under a Rule 10b5-1(c) trading plan adopted on March 12, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio management from discretionary, market-timed decisions.

How many PUMA Biotechnology (PBYI) shares did the director hold after these transactions?

After the June 12, 2026 sale, the director directly held 27,000 shares of PUMA Biotechnology Common Stock. This figure reflects his position immediately following the reported grant of 27,000 Restricted Stock Units and the subsequent sale of 27,000 shares.